Show Summary Details
Page of

EVAHEART® 2 Left Ventricular Assist Device System 

EVAHEART® 2 Left Ventricular Assist Device System
EVAHEART® 2 Left Ventricular Assist Device System

Tadashi Motomura

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 January 2021

The EVAHEART® left ventricular assist device (LVAD) system has been used in over 170 patients as bridge to transplantation (BTT) in Japan. Sixty percent of the patients are supported over 2 years, with the longest support time being 10.5 years. EVAHEART® is a centrifugal pump that has demonstrated high pulse pressure, excellent hemocompatibility, and low pump thrombosis. Recently, the EVAHEART® 2 was developed, which incorporates a smaller pump housing and a unique tip-less inflow cannula design. EVAHEART® 2 is currently approved by the PMDA in Japan and is under clinical trial in the United States for BTT and extended support.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.